To ascertain the burden of oral corticosteroid (OCS) complications and clinical occurrence of exacerbations in patients with myasthenia gravis (MG) during treatment with OCS in a large real-world population.
Approach:
Study Design: A retrospective longitudinal cohort study using US claims data from Optum’s de-identified Clinformatics® Data Mart Database.
Cohort Definition: Patients were categorized into an OCS cohort (those with OCS prescriptions) and a non-OCS cohort (those without OCS prescriptions) based on their treatment history.
Data Collection: Data included demographics, medical claims, and prescription records, allowing for longitudinal assessment of healthcare utilization and treatment patterns.
Key Findings:
Patients with continuous exposure to OCS over 12 months were more likely to experience complications such as infections and osteoporosis.
Exacerbations in myasthenia gravis were more frequent in patients undergoing OCS therapy compared to those not on OCS.
Interpretation:
The findings indicate a significant burden of complications and exacerbations associated with long-term OCS therapy in MG patients.
Limitations:
The study could not reliably determine the time from true disease onset to cohort index date due to data limitations.
The study was not restricted to newly diagnosed MG cases, which may affect the generalizability of the findings.
Conclusion:
There is an unmet need for alternative treatment options to better control myasthenia gravis symptoms and prevent exacerbations.
